Tue. Sep 27th, 2022

Substance (Drug) Abuse Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Substance (Drug) Abuse Therapeutics Market. 

The report provides a detailed description of the emerging drugs, including their type, stage, Mechanism of Action (MoA), Route of Administration (RoA), molecule type, inactive pipeline products, and NDA approvals. 

The report also covers in-depth commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed phase. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Substance (Drug) Abuse Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies in the Substance (Drug) Abuse Market.
  • It accesses the different therapeutic candidates segmented into early-stage (phase I), mid-stage (phase II), and late-stage (phase III) development. 
  • It assesses the targeted drug therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Substance (Drug) Abuse market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. 

Learn How the Ongoing Clinical & Commercial Activities will Affect the Substance (Drug) Abuse Therapeutic Segment:

https://www.delveinsight.com/sample-request/substance-drug-abuse-pipeline-insight

Substance (Drug) Abuse Therapeutics Analysis

Substance use disorder (SUD) is a serious condition, and it is not easy to treat. The best care and treatment involves trained professionals. Treatment starts by recognizing the problem. Although denial can be a common symptom of addiction, those who are addicted will have less denial if they are treated with respect, rather than being told what to do. The substance can be slowly withdrawn or stopped immediately. Support for physical or emotional symptoms, as well as staying drug-free, are key to treatment.

Some of the key companies in the Substance Use Disorder market include:

  • MediciNova
  • Omeros Corp. 
  • KemPharm
  • InterveXion Therapeutics
  • Pear Therapeutics

And others.

Substance Use Disorder Therapies Covered in the report include:

  • Ibudilast (MN-166)
  • OMS405
  • KP879
  • IXT-m200
  • reSET

And many others.

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:

https://www.delveinsight.com/sample-request/substance-drug-abuse-pipeline-insight

 Table of Content

  1. Report Introduction
  2. Executive Summary
  3. Substance (Drug) Abuse Current Treatment Patterns
  4. Substance (Drug) Abuse – DelveInsight’s Analytical Perspective
  5. Therapeutic Assessment
  6. Substance (Drug) Abuse Late Stage Products (Phase-III)
  7. Substance (Drug) Abuse Mid-Stage Products (Phase-II)
  8. Early Stage Products (Phase-I)
  9. Pre-clinical Products and Discovery Stage Products
  10. Inactive Products
  11. Dormant Products
  12. Substance (Drug) Abuse Discontinued Products
  13. Substance (Drug) Abuse Product Profiles
  14. Substance (Drug) Abuse Key Companies
  15. Substance (Drug) Abuse Key Products
  16. Dormant and Discontinued Products
  17. Substance (Drug) Abuse Unmet Needs
  18. Substance (Drug) Abuse Future Perspectives
  19. Substance (Drug) Abuse Analyst Review  
  20. Appendix
  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/substance-drug-abuse-pipeline-insight

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Contact Info:
Anuj Rawat
Email: [email protected]
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/substance-drug-abuse-pipeline-insight

Other Trending Healthcare Reports By DelveInsight

Substance (Drug) Abuse Market Insight

“Substance (Drug) Abuse Market Insights, Epidemiology and Market Forecast” report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the market trends in the 7MM.

Substance (Drug) Abuse Epidemiology Forecast

“Substance (Drug) Abuse Epidemiology Forecast” report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Substance (Drug) Abuse in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

By krehani

Leave a Reply

Your email address will not be published. Required fields are marked *